Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- East Bay cancer drug developer, jilted by Novartis, to cut 51 jobson January 10, 2020 at 12:05 pm
Aduro Biotech Inc. will cut nearly 60% of its workforce and close its European office a month after Swiss partner Novartis AG stepped away from a four-year cancer drug collaboration. The Berkeley ...
- Cancer Immunotherapy Market on eye to reach $117.11 Billion by 2022on January 9, 2020 at 8:11 pm
The Global Cancer Immunotherapy Marketwas valued at $45,471 million in 2015, and is projected to reach $117,114 million by 2022, growing at a CAGR of 14.5% from 2016 to 2022. The monoclonal antibodies ...
- Nano-sized copper compounds together with immunotherapy can kill cancer cellson January 9, 2020 at 12:14 pm
An interdisciplinary team of scientists from KU Leuven, the University of Bremen, the Leibniz Institute of Materials Engineering, and the University of Ioannina has succeeded in killing tumor cells in ...
- Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapyon January 9, 2020 at 4:27 am
Preclinical results published in Science Translational Medicine show that adding CD28 costimulatory bispecifics to CD3 bispecifics led to synergistic anti-tumor activity without inducing cytokine ...
- Cancer Immunotherapy Market 2020 Size, Share Metrics, Growth Trends and Forecast to 2026on January 9, 2020 at 1:27 am
New Jersey, United States, - Verified Market Research indicates that the Cancer Immunotherapy Market is expected to surge at a steady rate in the coming years, as economies flourish. The research ...
- Cancer death rate declines sharply, partly thanks to immunotherapyon January 8, 2020 at 6:45 pm
The U.S. cancer death rate has declined by the largest single-year amount on record, according to new statistics, improvement fueled in no small part by recent advances such as immunotherapy, the ...
- Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Proteinon January 8, 2020 at 5:19 am
This study uncovers an important layer in the regulation of key immune cell components that impact the effectiveness of cancer immunotherapy, highlighting the need to develop inhibitors for Tregs, in ...
- Cancer death rate posts biggest one-year drop everon January 8, 2020 at 4:08 am
For lung cancer, he pointed to new immunotherapy treatments and so-called targeted therapies that stop the action of molecules key to cancer growth. He predicted that the mortality rate would continue ...
- Immunotherapy for Lung Cancer Patient Ronon January 7, 2020 at 4:04 pm
When Ron, a husband and father who lives just outside of Richmond, Virginia, was diagnosed with lung cancer at age 56, he was stunned. After all, he was a competitive power lifter, often in the gym at ...
- Global Cancer Immunotherapy Market is Forecast to hit $115 Billion by 2023 - ReportsnReportson January 6, 2020 at 11:03 am
Immunotherapy is forecast to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. Multiple ...
via Bing News